Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
13. November 2024 08:06 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
Inventiva annonce un abstract « late breaker » et deux abstracts supplémentaires sur son médicament candidat principal, lanifibranor, lors du Liver Meeting™ 2023 organisé par l’AASLD
06. November 2023 16:00 ET
|
INVENTIVA
L’étude clinique de Phase II menée par Dr. Kenneth Cusi évaluant lanifibranor chez les patients atteints de diabète de type 2 et de MASLD a été sélectionnée comme « late breaker ».Deux abstracts...
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
06. November 2023 16:00 ET
|
INVENTIVA
The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
11. Oktober 2023 08:00 ET
|
Vir Biotechnology, Inc.
Eight abstracts highlighting new data from Vir's chronic hepatitis B and chronic hepatitis delta programs have been accepted for presentation at AASLD.
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
01. November 2022 16:01 ET
|
Arbutus Biopharma Corporation
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in...
Inventiva annonce la présentation d’un abstract scientifique lors du The Liver Meeting™ 2022 organisé par l’AASLD
21. Oktober 2022 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 21 octobre 2021 Daix (France) – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement...
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022
21. Oktober 2022 16:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
25. Juni 2022 07:00 ET
|
Vir Biotechnology, Inc.
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – ...
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
12. November 2021 08:00 ET
|
Vir Biotechnology, Inc.
– New data from ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate notable reductions in HBsAg and support their positive safety profiles – SAN FRANCISCO, Nov. 12, 2021 ...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
15. Oktober 2021 08:30 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health...